Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

News

  • Home
  •  
  • News



  • Most Read
  • Latest Comments
  • OncoSil Medical strengthens board with appointment of governance expert
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • OncoSil Medical strengthens board with appointment of governance expert
    • News

    Smart pain assessment app now used by more than half of Australia’s residential aged care providers
    Public
  • OncoSil Medical strengthens board with appointment of governance expert
    • News

    Fledgling fintech hopes millennials put their Douugh into micro-investing ‘super’ app
    Public
  • OncoSil Medical strengthens board with appointment of governance expert
    • News

    🎵 The knee bone’s connected to the… collagen rope device (?!)
    Public
  • OncoSil Medical strengthens board with appointment of governance expert
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial
    • Review
    • September 1, 2022

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • OncoSil Gains Momentum in Germany as 120 Hospitals Secure Negotiation Rights
    OncoSil Gains Momentum in Germany as 120 Hospitals Secure Negotiation Rights
    • News

  • OncoSil Medical strengthens board with appointment of governance expert
    OncoSil Medical strengthens board with appointment of governance expert
    • News

  • Trading the ASX – Get your head around economic data releases
    Trading the ASX – Get your head around economic data releases
    • News

  • Cost cutting is all the rage right now
    Cost cutting is all the rage right now
    • News

  • Shareholders left empty-handed with Booktopia sold by administrators for no return
    • News

    Shareholders left empty-handed with Booktopia sold by administrators for no return

    After months of uncertainty having struggled with solvency and a $6 million fine from the ACCC, Australia’s largest online book retailer Booktopia (ASX: BKG) has been sold by administrators in a move that will manage the financially distressed company, but see shareholders returned nothing.  The sale was finalised on Friday, 16 August by administrators from

    Read More
    Public
  • Strategic win for Control Bionics as new HCPCS gets approved for NeuroNode
    • News

    Strategic win for Control Bionics as new HCPCS gets approved for NeuroNode

    The Centers for Medicare & Medicaid Services has approved a new Healthcare Common Procedure Coding System code for the NeuroNode, patent technology by Control Bionics (ASX: CBL).  This approval, effective from 1 October 2024, introduces a reimbursement rate of US$4,300 for the NeuroNode, a significant enhancement from the previous reimbursement conditions. Control Bionics is a

    Read More
    Public
  • Archer Materials advances Biochip technology with new design for manufacturing to be tested in Finland
    • News

    Archer Materials advances Biochip technology with new design for manufacturing to be tested in Finland

    Australian semiconductor company Archer Materials (ASX: AXE) has progressed its latest Biochip design to the next phase of development by dispatching it to the VTT Technical Research Centre of Finland Ltd (VTT) for manufacturing. The Biochip’s newest graphene field-effect transistor (gFET) design, which was announced in July 2024, marks a milestone in enhancing it’s functionality,

    Read More
    Public
  • Despite economic uncertainty and high interest rates, Domain delivers bumper FY24 result
    • News

    Despite economic uncertainty and high interest rates, Domain delivers bumper FY24 result

    As Australia battles economic uncertainty which has seen a major pullback in household spending, mortgages stress is pushing many families to breaking point with a bumper result for property tech company Domain Holdings (ASX: DHG) which has seen more listings at a time when borrowing power is weakened due to high interest rates.  For the

    Read More
    Public
  • Nido Education flags profit downgrade amid delays in new childcare centre openings
    • News

    Nido Education flags profit downgrade amid delays in new childcare centre openings

    Cost-of-living pressures and the inflationary pressure on raw materials is having an impact on childcare operator Nido Education (ASX: NDO) which has forewarned that it is unlikely to meet the profit expectations for 2024 that were outlined in their IPO Prospectus when listing on the ASX in October 2023.  The childcare centre operator has cited

    Read More
    Public
  • Firebrick Pharma expands Nasodine reach to Philippines under amended licence
    • News

    Firebrick Pharma expands Nasodine reach to Philippines under amended licence

    Firebrick Pharma (ASX: FRE) is making waves with its Nasodine Nasal Spray disinfectant, having recently executed an amended licence and distribution agreement to bring the product to the Philippines.  The amended agreement with S.V. More Pharma Corporation (SV More) allows for the local manufacture of Nasodine, shifting from its previous importation from Australia. This strategic

    Read More
    Public
  • Wellnex Life’s entry into UK wellness market kicks off with first purchase order from Haleon
    • News

    Wellnex Life’s entry into UK wellness market kicks off with first purchase order from Haleon

    Australian health company, Wellnex Life (ASX: WNX) has secured a pivotal partnership and received its first purchase order from global provider Haleon to supply Paracetamol Soft Gel Liquid Analgesic to the UK market. In today’s health-conscious world where consumers demand innovative and effective solutions, Wellnex Life’s partnership with Haleon positions the Company at the forefront

    Read More
    Public
  • Seven West Media battles for survival amid television landscape turmoil and plummeting earnings
    • News

    Seven West Media battles for survival amid television landscape turmoil and plummeting earnings

    When James Warburton handed over the reins of Seven West Media (ASX: SWM) to Jeff Howard in April 2024, it was always going to be a baptism by fire with the media giant grappling with formidable challenges in an increasingly difficult television landscape.  This was reflected with the Company reporting a significant downturn in earnings,

    Read More
    Public
  • Bio-Gene and Envu join forces to tackle mosquitoes with Flavocide
    • News

    Bio-Gene and Envu join forces to tackle mosquitoes with Flavocide

    Bio-Gene Technology Limited (ASX: BGT), an Australian innovator in bio-insecticides, has entered into a strategic collaboration with Envu, a global provider of environmental solutions to evaluate its flagship product Flavocide for use in public and private sector mosquito management. Over half of the global population is at risk from vector-borne diseases like malaria, Zika virus,

    Read More
    Public
  • Apiam deploys revolutionary tick and flea preventative for Australian dog owners, a major growth driver for FY25
    • News

    Apiam deploys revolutionary tick and flea preventative for Australian dog owners, a major growth driver for FY25

    Australian pet owners now have access to revolutionary tick and flea preventative with vet clinic operator Apiam Animal Health (ASX: AHX) having commenced sales of the injectable treatment which provides up to 12 months of  control of paralysis ticks and treatment and prevention from flea infestations. The new technology was developed by pharmaceuticals giant Merck

    Read More
    Public
  • «
  • ‹
  • 23
  • 24
  • 25
  • 26
  • 27
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.